Evidence map›Paper›PMID 34990493›Full record

Observational studyPloS one2022

The lower airways microbiome and antimicrobial peptides in idiopathic pulmonary fibrosis differ from chronic obstructive pulmonary disease.

Kristel S Knudsen, Sverre Lehmann, Rune Nielsen, Solveig Tangedal, Ingvild Haaland, Pieter S Hiemstra, Tomas M Eagan

Open access · goldAbstract readComparative StudyObservational Study
In one paragraph

Observational study in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Kristel S KnudsenDepartment of Clinical Science, University of Bergen, Bergen, Norway.ORCID 0000-0001-5129-3892
Sverre LehmannDepartment of Clinical Science, University of Bergen, Bergen, Norway.
Rune NielsenDepartment of Clinical Science, University of Bergen, Bergen, Norway.
Solveig TangedalDepartment of Clinical Science, University of Bergen, Bergen, Norway.
Ingvild HaalandDepartment of Clinical Science, University of Bergen, Bergen, Norway.
Pieter S HiemstraDepartment of Pulmonology, Leiden University Medical Center, Leiden, Netherlands.
Tomas M EaganDepartment of Clinical Science, University of Bergen, Bergen, Norway.ORCID 0000-0001-8725-9960
Haukeland University Hospital · NOUniversity of Bergen · NOLeiden University Medical Center · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe lower airways microbiome and host immune response in chronic pulmonary diseases are incompletely understood. We aimed to investigate possible microbiome characteristics and key antimicrobial peptides and proteins in idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD).

methods12 IPF patients, 12 COPD patients and 12 healthy controls were sampled with oral wash (OW), protected bronchoalveolar lavage (PBAL) and right lung protected sterile brushings (rPSB). The antimicrobial peptides and proteins (AMPs), secretory leucocyte protease inhibitor (SLPI) and human beta defensins 1 and 2 (hBD-1 & hBD-2), were measured in PBAL by enzyme linked immunosorbent assay (ELISA). The V3V4 region of the bacterial 16S rDNA gene was sequenced. Bioinformatic analyses were performed with QIIME 2.

resultshBD-1 levels in PBAL for IPF were lower compared with COPD. The predominant phyla in IPF were Firmicutes, Bacteroides and Actinobacteria; Proteobacteria were among top three in COPD. Differential abundance analysis at genus level showed significant differences between study groups for less abundant, mostly oropharyngeal, microbes. Alpha diversity was lower in IPF in PBAL compared to COPD (p = 0.03) and controls (p = 0.01), as well as in rPSB compared to COPD (p = 0.02) and controls (p = 0.04). Phylogenetic beta diversity showed significantly more similarity for IPF compared with COPD and controls. There were no significant correlations between alpha diversity and AMPs.

conclusionsIPF differed in microbial diversity from COPD and controls, accompanied by differences in antimicrobial peptides. Beta diversity similarity between OW and PBAL in IPF may indicate that microaspiration contributes to changes in its microbiome.

Indexed as

AgedAged, 80 and overAntimicrobial PeptidesBacteriabeta-DefensinsBronchoalveolar Lavage FluidCase-Control StudiesFemaleHumansIdiopathic Pulmonary FibrosisMaleMicrobiotaMiddle AgedPhylogenyPulmonary Disease, Chronic ObstructiveRNA, Ribosomal, 16SAntimicrobial Peptidesbeta-DefensinsRNA, Ribosomal, 16SSecretory Leukocyte Peptidase InhibitorSLPI protein, human

Identifiers

PMID34990493
PMCPMC8735599
OpenAlexW4206827622

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.